Uploaded October 2026 | Updated November 2026, 10 hours ago
Lukasz Jarzyna, Vice President of Rare Disease at LEO Pharma, discusses the Priority Review for dersimelagon in the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
For the full interview, visit checkrare.com/priority-review-for-dersimelagon-in-the-treatment-of-erythropoietic-protoporphyria-and-x-linked-protoporphyria
Lukasz Jarzyna, Vice President of Rare Disease at LEO Pharma, discusses the Priority Review for dersimelagon in the treatment of erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP).
For the full interview, visit checkrare.com/priority-review-for-dersimelagon-in-the-treatment-of-erythropoietic-protoporphyria-and-x-linked-protoporphyria










